Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  draadje Malaria

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

draadje Malaria

439 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 22 »» | Laatste | Omlaag ↓
  2. durobinet 9 mei 2009 17:27
    Deels bekend, deels misschien niet.
    vr.gr. duro

    Tomatoes, mosquitoes and lasers: bizarre projects receive Gates grantsHealth research grants are designed to encourage scientists to pursue bold ideas that could lead to breakthroughs

    guardian.co.uk, Monday 4 May 2009 21.18 BST Article historyCan tomatoes be taught to make antiviral drugs for people who eat them? Would zapping your skin with a laser make your vaccination work better? Could malaria-carrying mosquitoes be given a teensy head cold that would prevent them from sniffing out a human snack bar?

    These are among 81 projects awarded $100,000 grants today by the Bill and Melinda Gates Foundation in a bid to support innovative unconventional global health research.

    The five-year health research grants are designed to encourage scientists to pursue bold ideas that could lead to breakthroughs, focusing on ways to prevent and treat infectious diseases, such as HIV, malaria, tuberculosis, pneumonia and diarrhoeal diseases.

    The foundation said grant recipient Eric Lam at Rutgers University in New Jersey is exploring tomatoes as a antiviral drug delivery system.

    Researchers at the University of Exeter in Devon will seek to build an inexpensive instrument to diagnose malaria by using magnets to detect the waste products of the malaria parasite in human blood.

    Mei Wu at Massachusetts General Hospital and Harvard Medical School will be getting a grant to see if shooting a laser at a person's skin before administering a vaccine can enhance immune response.

    And Thomas Baker at Pennsylvania State University wants to see if malaria-carrying mosquitoes can be infected with a fungus that would act like a cold, suppressing the sense of smell that they use to find people as sources of blood.

    The foundation also announced plans today to spend $73m over the next five years to help small farmers in impoverished countries. That programme was outlined by foundation CEO Jeff Raikes at a water conference held at the University of Nebraska-Lincoln.

    Raikes, a former Microsoft executive, said spending on agriculture in sub-Saharan African countries, where the foundation focuses much of its poverty-fighting efforts, accounts for less than 5% of their total government budgets. And from 1985 to 2005, spending as a percentage of government budgets decreased in donor countries, he said, including the US.

    The agriculture grants include $40m to develop drought-tolerant corn, $13m for more efficient irrigation, and $10m to help women develop education and training programmes related to agriculture.

    The largest philanthropic foundation in the world, the Gates Foundation gave out $2.8bn last year. It has said payouts this year would grow by about 10%, less than previously planned, because of the troubled economy.

    The foundation was started in 1994 by Microsoft co-founder Bill Gates and his wife and has the international goals of overcoming hunger, poverty and disease. In America, its focus is on education, which receives about a quarter of its grant dollars.
  3. flosz 20 mei 2009 09:44
    Potential new malaria vaccine enters trials
    18 May 2009
    Paul Chinnock
    The first tests have begun, in healthy adult volunteers in the USA, of a potential new malaria vaccine. The vaccine – developed in a public-partnership between the PATH Malaria Vaccine Initiative (MVI) and US company, Sanaria – is unlike other malaria vaccine candidates in that it uses a weakened form of the whole malaria parasite harvested from irradiated mosquitoes. Other candidates have instead used small portions of the parasite.

    Sanaria is aiming to begin trials in Africa next year and hopes to achieve higher rates of protection than have so far been reached with the most advanced malaria vaccine currently on trial, RTS,S manufactured by GlaxoSmithKline – which seems likely to offer only around 50-60% protection.
    www.tropika.net/svc/news/20090518/Chi...
    *********************
    Again:

    Uit post aossa, okt. 2007:
    Is het geen noodzaak dat Crucell vaccine tesamen met het GSK wordt ontwikkeld en/of goedgekeurd. Eens het Ad35 van Crucell stand-alone goedgekeurd, zou het in een combinatie 'extended application' extra waarde (betere immuun respons) kunnen geven aan het GSK RTS, S vaccine, waarbij het Ad35 vaccine als eerste wordt toegediend en de T-cel immuniteit activeert ten voordele van de 2 volgende inentingen met het GSK vaccine. Respons >90% ipv 65% !
    Meer via:
    crucell.yourbb.nl/viewtopic.php?f=7&t...
    www.iex.nl/forum/topic.asp?forum=228&...
  4. flosz 27 mei 2009 16:18
    A way to make drugs for poor countries
    Kai Ryssdal: Nearly a million people die of malaria every year, most of them young children in sub-Saharan Africa. A public-private venture that includes $200 million from the Gates Foundation is working on a vaccine. It's about to do its final tests. And if the vaccine works, the collaboration that produced it could offer a viable business model for developing drugs for poorer countries. Megan Williams reports now from Gabon, in central Africa.
    ________________________________________
    MEGAN WILLIAMS: Dr. Maxime Agnandji peers into a microscope at the Albert Schweitzer Hospital lab in Lamberene, Gabon.
    The 35-year-old who grew up in the country heads the research unit here, as part of the biggest medical trial ever held in Africa. A malaria vaccine test involving 16,000 kids and 11 different research centers across the continent.
    MAXIME AGNANJDI: Basically I want to stay here to develop my career here.
    Agnanjdi is one of the principal investigators for the final test of the vaccine, called RTSS. So far, it's been shown to cut the rate of severe malarial infection by half. Agnanjdi says it's not only exciting to work on a solution to a mainly African problem, but on a project that's changing the face of medical research in Africa.
    AGNANJDI: Since the 10 last years there is improvement in training, to control diseases. I've met many, many doctors from different countries, all are from Africa. Young researchers from Africa.
    The Gates foundation decided to invest in the malaria vaccine research after scientists at the drug company Glaxo-Smith-Kline showed it had real potential. But for big drug companies vaccines in Africa just aren't profitable. People are too poor to pay. Without the Gates funding, the malaria vaccine wouldn't have been developed.
    Rip Ballou of the Gates Foundation has been part of the quest for a malaria vaccine for more than two decades.
    RIP BALLOU: If you go back 20 years, most research being done in Africa was being done by Europeans and Americans who came here because there's all these disease challenges, fascinating problems. But there was no resources coming from the African host nations.
    Unlike most drug trials in Africa, the bulk of the funding has been invested right here, in Africa. By building first-rate hospitals and labs and upgrading facilities and equipment to Western standards. And, of course, developing motivated scientists like DR. Maxime Agnandji.
    BALLOU: You know, I think one of great things that's happened with this program over the last several years is that we've identified a whole cadre of really talented African investigators to do this.
    If this last trial of the RTSS vaccine proves effective, then in a few years comes the next hurdle, making it affordable to the people who so desperately need it. Glaxo-Smith-Kline is contractually obliged by the Gates Foundation to set a ceiling on the price, but it can also make a profit. Joe Cohen is the Glaxo-Smith-Kline scientist who invented the vaccine. He insists low cost is a priority.
    JOE COHEN: It makes sense. This malaria vaccine, in contrast to many other vaccines, is exclusively meant for African children. There is no other market for it. It would be crazy for us after 25 years of work on malaria vaccine to do anything that would prevent this vaccine from being accessible and to see this vaccine just sitting on a shelf.
    tinyurl.com/ps8vgo
  5. forum rang 10 voda 29 mei 2009 15:11
    Malariaparasiet resistent tegen huidige medicijnen
    29 mei 2009, 11:42 | ANP
    PHNOM PENH (ANP) - Internationale wetenschappers zijn er in Cambodja achter gekomen dat de parasieten die daar malaria veroorzaken, resistent worden voor het meest effectieve medicijn tegen de aandoening. Volgens de BBC is het onduidelijk waarom Cambodja kennelijk een kweekvijver voor deze resistentie is.

    Tot nu toe zorgde de werkzame stof artemisinine ervoor dat de dodelijke malariaparasiet binnen drie dagen uit het bloed was verdwenen. Twee verschillende onderzoeksteams zijn er bij nieuwe tests onafhankelijk van elkaar achtergekomen dat het nu vier tot vijf dagen duurt voordat de parasiet is verdwenen. Dit zijn de eerste signalen van weerstand van de parasiet.

    Volgens onderzoekers zou volledige resistentie een wereldwijde ramp voor de volksgezondheid zijn. Al twee keer eerder zijn de parasieten in Zuidoost Azië resistent geworden voor het antimedicijn. Van daaruit werd de resistentie verspreid over de rest van de wereld. ,,Als het weer gebeurt en volledig resistente parasieten zich verspreiden van Azië tot Afrika, is dat rampzalig voor de beheersing van malaria, zeiden wetenschappers tegen de BBC.

  6. flosz 29 mei 2009 17:01
    Uit 2006:
    WASHINGTON, Jan 19 (Reuters) - The World Health Organization asked pharmaceutical companies on Thursday to end the marketing and sale of "single-drug" artemisinin malaria medicines, in order to prevent malaria parasites from developing resistance to the drug.
    The use of single-drug artemisinin treatment, or "monotherapy," hastens development of resistance by weakening but not killing the parasite, WHO said in new malaria treatment guidelines.

    "We request pharmaceutical companies to immediately stop marketing single-drug artemisinin tablets and instead market artemisinin combination therapies only," WHO Director-General Dr. Lee Jong-wook said in a statement.
    www.iex.nl/forum/topic.asp?forum=228&...
  7. flosz 3 juni 2009 22:34
    Fact sheet: Phase 3 trial of RTS,S

    The launch of the Phase 3 trial of GlaxoSmithKline’s (GSK) malaria vaccine candidate, RTS,S, marks a major research milestone after more than 20 years of research and development. Launched in May 2009, the Phase 3 trial will include 11 sites in Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania, as required local and national reviews are obtained. Together, the 11 sites will eventually enroll up to 16,000 children and infants, making this the largest malaria vaccine trial to date.
    www.malariavaccine.org/files/05272009...
  11. flosz 4 juni 2009 08:43
    Er is nog steeds samenwerking sam….
    J. Cohen als in GSK’S RTS,S/AS02A J. Cohen………

    Vaccine. 2008 Apr 16
    Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice.

    Shott JP, McGrath SM, Pau MG, Custers JH, Ophorst O, Demoitié MA, Dubois MC, Komisar J, Cobb M, Kester KE, Dubois P, Cohen J, Goudsmit J, Heppner DG, Stewart VA.
    Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.

    Falciparum malaria vaccine candidates have been developed using recombinant, replication-deficient serotype 5 and 35 adenoviruses (Ad5, Ad35) encoding the Plasmodium falciparum circumsporozoite surface protein (CSP) (Ad5.CS, Ad35.CS) (Crucell Holland BV, Leiden, The Netherlands). To evaluate the immunogenicity of these constructs, BALB/cJ mice were immunized twice with either Ad5.CS, Ad35.CS, empty Ad5-vector (eAd5), empty Ad35 vector (eAd35), or saline. Another group received the CSP-based RTS,S malaria vaccine formulated in the proprietary Adjuvant System AS01B (GlaxoSmithKline Biologicals, Rixensart, Belgium). Here we report that Ad5.CS, Ad35.CS, and RTS,S/AS01B, elicited both cellular and serologic CSP antigen-specific responses in mice. These adenoviral vectors induce strong malaria-specific immunity and warrant further evaluation.
    PMID: 18455276
    www.ncbi.nlm.nih.gov/pubmed/18455276?...

    (Dr. Joe Cohen, one of the inventors and original patent holder of the RTS,S/AS02A malaria vaccine, joined GSK Bio in 1984)

    Uit: Malaria: The end of the beginning
    Hill's doubts about the vaccine bolster a more general frustration with what he sees as GSK's go-it-alone approach, “unconnected to the other 12 or 15 groups developing vaccines” (see table 1). He and others want different vaccines to be combined with RTS,S in Phase II testing, suspecting efficacy might be greatly enhanced. Heppner, for example, says that results of studies he and his colleagues have carried out on macaques indicate that combining an adenovirus-based vaccine made by the Netherlands biotech company CruCell with RTS,S would offer much better effects[10]: “My hope is that a way can be found to evaluate this clinically just as we've done for earlier improvements of RTS,S.” Ballou says that although progress in studying this combination has been stalled for “various business reasons”, several collaborative efforts continue.
    *****************

    For a malaria vaccine to be used in a national programme, it has to be 70% effective or more. Using a mosquito net alone gives 60% protection.
    ******************************
    In March 2003, we entered into collaboration with the Walter Reed Army Institute of Research (WRAIR) and GlaxoSmithKline Biologicals (GSK) under a Cooperative Research and Development Agreement (CRADA). In line with this agreement, we have completed work with WRAIR and GSK to evaluate our AdVac® malaria vaccine candidate. Our vaccine candidate was tested as a stand-alone vaccine and in combination with GSK’s RTS,S malaria vaccine candidate. These studies have shown that Crucell’s AdVac® vaccine candidate efficiently primed and/or boosted malaria specific immune responses.

    The GSK malaria vaccine candidate RTS,S has, as a stand-alone vaccine, been shown to confer partial protection to human volunteers in both a laboratory challenge model conducted at WRAIR and under natural challenge conditions in a field study conducted in the Gambia. Phase IIb pediatric trials conducted with RTS,S in Mozambique and reported in The Lancet medical journal in October 2004 and 2007 demonstrated further promising results, with the vaccine protecting some infants against infection and making the course of the disease less serious and life threatening in others.

    In March 2004 it was announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), will support the development of our candidate malaria vaccine. The agreement has an estimated value of up to US$ 3.5 million and covers process development of the candidate AdVac-based malaria vaccine including the production of clinical trial material and Investigational New Drug (IND) filing. The work is being done under a subcontract agreement with Science Applications International Corporation (SAIC).

    In partnership with the NIAID, Crucell’s malaria vaccine entered a Phase I trial in the US in Q4 2006. The study is being carried out on two sites, VanderBilt and Stanford University. The first and second cohorts, comprising 18 and 17 volunteers respectively, have been successfully enrolled. No serious adverse side-effects have been reported to date. Current plans call for subsequent enrollment of two additional cohorts at higher vaccine doses, provided the vaccine has an appropriate safety profile. Following review of the safety data by a Safety Monitoring Committee, a decision has been made to begin recruitment of the third cohort.

    **********************

    Uit post aossa, okt. 2007:
    Is het geen noodzaak dat Crucell vaccine tesamen met het GSK wordt ontwikkeld en/of goedgekeurd. Eens het Ad35 van Crucell stand-alone goedgekeurd, zou het in een combinatie 'extended application' extra waarde (betere immuun respons) kunnen geven aan het GSK RTS, S vaccine, waarbij het Ad35 vaccine als eerste wordt toegediend en de T-cel immuniteit activeert ten voordele van de 2 volgende inentingen met het GSK vaccine. Respons >90% ipv 65% !
    Bijlage:
  14. [verwijderd] 22 juni 2009 23:33
    Misschien een kleine tegenstrijdigheid?

    Adenovirus Vaccine for Malaria

    Volgens Clinical Trials website:
    clinicaltrials.gov/ct2/show/NCT003711...
    This study is currently recruiting participants.

    Locations
    United States, California
    Stanford University Recruiting
    Stanford, California, United States, 94305
    vaccines.stanford.edu/clinical_trials...

    quote:

    Stanford university schreef:

    NIH-Sponsored Malaria Vaccine Trial (Enrollment closed)
    [/quote]
    United States, Tennessee
    Vanderbilt University Recruiting
    Nashville, Tennessee, United States, 37232
    www.vanderbilthealth.com/clinicaltria...

    [quote=Vanderbilt University]
    ...........
    Zeer waarschijnlijk heeft Stanford iedereen binnen en Vanderbilt nog niet.
    Note: mailtje is al naar Tanya verstuurd.
  15. flosz 18 juli 2009 12:21
    17-Jul-2009
    American Society for Microbiology

    Chronicle of a century's search for an elusive malaria vaccine

    Malaria is one of humankind's greatest killers, yet despite the best efforts of scientists, an effective vaccine is still not available to prevent it. A new book from ASM Press, The Elusive Malaria Vaccine: Miracle or Mirage? tells the story of the search for a still unrealized vaccine.
    Chronicling a 100-year quest, this book tells the fascinating story of the hunt for the still-elusive malaria vaccine. Its clear, engaging style makes the book accessible to a general audience and brings to life all the drama of the hunt, celebrating the triumphs and documenting the failures.
    Authored by Irwin W. Sherman of the University of California, Riverside, The Elusive Malaria Vaccine: Miracle or Mirage? is based on his thorough investigation of the scientific literature as well as his first-hand interviews with today's pioneers in malaria vaccine research. As a result, the book offers remarkable insights into the keys to a successful malaria vaccine and the obstacles hindering its development.
    Malaria currently afflicts some 300 to 500 million people. Moreover, malaria infections have begun to spread and surge in places previously free from the disease. With the book's easy-to-follow coverage of such topics as immunity, immunology, recombinant DNA, and monoclonal antibodies, readers gain a new understanding of the disease itself, the importance of microbe hunters, and the need for responsible leadership to face the challenges that lie ahead in the battle against malaria.
    "The hunt for a malaria vaccine has been unfolding for a century. It has been punctuated by periods of intense activity and excitement followed by inaction and boredom. The quest has been enlivened by controversy; there have been wars of words, and errors have been made, some honest but sometimes not. Ideas have been stolen, credit for discovery has gone unacknowledged, and there have been and continue to be intense rivalries with clashes of ego and even scandals. This book tells of slow and erratic research, the promises of success and the disappointing failures, and the fierce competition between microbe hunters who have had as their single goal a protective malaria vaccine able to reduce morbiditiy and mortality by one of the world's most notorious assassins," says Sherman.
    www.eurekalert.org/pub_releases/2009-...
    ********************

    Crucell/ MVI/ AdVac®-based malaria vaccine/ Preclinical
    Crucell/NIAID/ AdVac®-based malaria vaccine/ Clinical
    www.ifpma.org/documents/NR12400/Statu...
  16. ved 23 juli 2009 23:36
    July 22, 2009

    Vaccine Blocks Malaria Transmission in Lab Experiments

    Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked the sexual development of the malaria-causing parasite, Plasmodium, as it grows within the mosquito. Sexual development is a critical step in the parasite’s life cycle and necessary for continued transmission of malaria from mosquitoes to humans. The study is published in the July 22 edition of the journal PLoS ONE.

    “Development of a successful transmission-blocking vaccine is an essential step in efforts to control the global spread of malaria. In our study, we demonstrate the relative ease of expression and induction of potent transmission-blocking antibodies in mice and non-human primates. This approach provides a compelling rationale and basis for testing a transmission-blocking vaccine in humans,” said Nirbhay Kumar, PhD, senior author of the study and professor in Johns Hopkins Bloomberg School of Public Health’s W. Harry Feinstone Department of Molecular Microbiology and Immunology.

    For the study, the research team expressed full-length Pfs48/45 in E. coli bacteria to produce the vaccine. Previous attempts to fully express the protein had not been successful. The vaccine was first given to mice in the laboratory. The vaccine was also tested in non-human primates (Olive baboons) in Kenya with similar results. According to the study, a single-dose vaccine provided a 93 percent transmission-blocking immune response, reaching greater than 98 percent after a booster was given several months later.

    “This is an exciting beginning to what might become an important tool in the arsenal for malaria control and progressive elimination of malaria transmission,” said Kumar. There is no animal reservoir for human malaria and in that regard it is possible to gradually reduce malaria transmission to a point of almost eradication. However, Kumar cautioned that more research is needed to achieve that goal. For one, similar research efforts are needed to reduce transmission of Plasmodium vivax, another major human malaria parasite.

    Malaria affects greater than 500 million people worldwide and is estimated to kill over one million people each year, most of whom are children living in Africa.

    In addition to Kumar, “A Potent Malaria Transmission-Blocking Vaccine Based on Condon Harmonized Full Length Pfs48/45 Expressed in E. Coli” was published by Debabani Roy Chowdhury, a postdoctoral fellow of the Johns Hopkins Bloomberg School of Public Health; Evelina Angov of the U.S. Military Malaria Vaccine Program; and Thomas Kariuki of the Institute of Primate Research in Nairobi, Kenya.

    The research was supported by grants from the National Institutes of Health and the Johns Hopkins Malaria Research Institute.

    Public Affairs media contact for the Johns Hopkins Bloomberg School of Public

    www.jhsph.edu/publichealthnews/press_...
  17. forum rang 4 aossa 27 juli 2009 15:21
    GenVec Expands Contract Supporting Malaria Vaccine Program

    GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC - News) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines.

    "We appreciate the continued support from MVI and USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated Dr. Joseph Bruder, head of GenVec's malaria program.

    About GenVec
    GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

    On the Internet:
    Program for Appropriate Technology in Health (PATH): www.path.org
    PATH Malaria Vaccine Initiative: www.malariavaccine.org

    USAID Malaria Vaccine Development Program: www.usaid.gov/our_work/global_health/...
    USAID: www.usaid.gov

    finance.yahoo.com/news/GenVec-Expands...
  19. pardon 29 juli 2009 08:11
    About us Over ons Malaria vaccines Malaria vaccins Research and development Onderzoek en ontwikkeling Preparing for vaccines Voorbereidingen voor vaccins Publications and resources Publicaties en middelen Phase 3 malaria vaccine trial begins—final testing of RTS,S Fase 3 malariavaccin proces begint-eindbeproeving van RTS, S
    African research centers partner with GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative Afrikaanse onderzoekscentra partner met GlaxoSmithKline Biologicals en het PATH Malaria Vaccine Initiative
    BAGAMOYO, TANZANIA, May 27, 2009 — The Phase 3 trial of the most clinically advanced malaria vaccine candidate began May 26 with inoculations administered at the Bagamoyo Research and Training Centre of the Ifakara Health Institute (IHI) in Tanzania. BAGAMOYO, Tanzania, 27 mei 2009 - De fase 3-studie van de meest geavanceerde klinische malaria vaccin kandidaat begon 26 mei met inentingen toegediend op de Bagamoyo Research and Training Centre van de Ifakara Health Institute (IHI) in Tanzania. In the coming months, the trial is expected to start in other countries across sub-Saharan Africa and will enroll up to 16,000 children and infants. In de komende maanden, het proces zal naar verwachting starten in andere landen in Afrika bezuiden de Sahara en zal inschrijven tot en met 16.000 kinderen en zuigelingen.

    Developing a vaccine against malaria, a scientific challenge for decades, is critical to defeating the disease. Ontwikkeling van een vaccin tegen malaria, een wetenschappelijke uitdaging voor decennia, is essentieel voor het verslaan van de ziekte. A vaccine would complement existing interventions, such as bed nets and effective drug therapies. Een vaccin zou een aanvulling op de bestaande interventies, zoals muskietennetten en effectief geneesmiddel therapieën. Despite current control efforts, malaria still kills approximately 900,000 people every year, with most deaths occurring in Africa among children under the age of five. Ondanks de huidige controle-inspanningen, malaria doodt ongeveer 900.000 mensen per jaar, waarbij de meeste sterfgevallen die zich in Afrika onder kinderen onder de leeftijd van vijf. GlaxoSmithKline (GSK) Biologicals' RTS,S is the first malaria vaccine to demonstrate promising safety and significant efficacy to warrant Phase 3 testing and is the leading candidate in the effort by the PATH Malaria Vaccine Initiative (MVI) to develop a malaria vaccine. GlaxoSmithKline (GSK) Biologicals' RTS, S is de eerste malaria vaccin aan te tonen veelbelovende veiligheid en werkzaamheid significante om fase 3 testen en is de belangrijkste kandidaat bij de inspanning van de PATH Malaria Vaccine Initiative (MVI) ontwikkeling van een malaria vaccin.

    Recent Phase 2 studies showed that over an eight-month follow-up period, RTS,S reduced the risk of clinical episodes of malaria by 53 percent and has a promising safety and tolerability profile when used alongside standard infant vaccines. Fase 2 Recente studies toonden aan dat meer dan een acht maanden durende follow-up periode, RTS, S verminderde het risico van de klinische episodes van malaria met 53 procent en heeft een veelbelovende veiligheid en verdraagzaamheid profiel bij gebruik naast standaard zuigeling vaccins. The Phase 3 trial builds on more than ten years of clinical research in Africa, including the first proof-of-concept study in children in 2004 and a proof-of-concept study in infants in 2007. De fase 3-onderzoek is gebaseerd op meer dan tien jaar van klinisch onderzoek in Afrika, inclusief de eerste proof-of-concept-studie bij kinderen in 2004 en een proof-of-concept studie bij zuigelingen in 2007.

    The culmination of more than twenty years of research by an innovative public-private partnership among MVI, GSK Biologicals, and their partners in Africa, the Phase 3 trial is an important milestone—but challenges remain. Het hoogtepunt van meer dan twintig jaar onderzoek door een innovatief publiek-privaat partnerschap tussen MVI heeft GSK Biologicals, en hun partners in Afrika, het fase 3-onderzoek is een belangrijke mijlpaal, maar uitdagingen blijven bestaan. Scientists will continue to work in collaboration to ensure this vaccine, if proven effective, reaches those who need it most—the children of Africa. Wetenschappers zullen blijven werken samen om ervoor te zorgen dit vaccin, indien bewezen effectief zijn, bereikt die het het meest nodig hebben-de kinderen van Afrika.

    The Phase 3 trial De fase 3 trial
    As the trial extends to other sites, research centers across Africa will work with GSK Biologicals and MVI to further evaluate the efficacy and safety of the RTS,S vaccine. Als de proef uitgebreid naar andere sites, onderzoek-centra in heel Afrika zal met GSK Biologicals en MVI verder evalueren van de werkzaamheid en veiligheid van de RTS, S vaccins. The full Phase 3 trial is designed to demonstrate how the vaccine performs in a large group of children and infants in different transmission settings across a wide geographic region. Het volledige proces Fase 3 is ontworpen om aan te tonen hoe het vaccin op in een grote groep kinderen en baby's in de verschillende transmissie-instellingen over een brede geografische regio.

    "We are embarking on a scientific endeavor that could mean a new future for Africa," said Dr. Salim Abdulla, a principal investigator and director of IHI. "We gaan beginnen op een wetenschappelijke proberen dat zou kunnen betekenen een nieuwe toekomst voor Afrika", aldus dr. Salim Abdulla, een van de belangrijkste onderzoeker en directeur van IHI. "Building on the research our institute conducted for the Phase 2 trials, we are committed to advancing this vaccine, which could potentially save hundreds of thousands of lives." "Voortbouwend op het onderzoek ons instituut verricht voor de Fase 2 proeven, zijn wij er aan de voortgang van dit vaccin, dat zou kunnen slaan honderdduizenden levens."

    The clinical development of RTS,S is being implemented by the Clinical Trial Partnership Committee (CTPC), a collaboration of leading African research institutes, Northern academic partners, MVI and GSK Biologicals, with support from the Malaria Clinical Trials Alliance. De klinische ontwikkeling van de RTS, S wordt uitgevoerd door de Clinical Trial Partnerschap Comite (CTPC), een samenwerkingsverband van vooraanstaande onderzoeksinstituten in Afrika, Noord-academische partners, MVI en GSK Biologicals, met steun van de Malaria Clinical Trials Bondgenootschap.

    "This study will be the largest trial conducted in Africa of a vaccine specifically designed to help African children. We have great appreciation for the families and children participating," said Eusebio Macete, chair of the CTPC, and director of the Centro de Investigação em Saúde de Manhiça, Mozambique , another site that will engage in the Phase 3 trial. "Deze studie zal de grootste proef die in Afrika van een vaccin specifiek ontworpen om te helpen de Afrikaanse kinderen. Wij hebben grote waardering voor de gezinnen en kinderen die deelnemen", aldus Eusebio Macete, voorzitter van de CTPC, en directeur van het Centro de Investigação em Saúde de Manhiça, Mozambique, een andere site die zich in de fase 3 trial. "Development of RTS,S in Africa has strengthened research capacity that will far outlast the trials." "Ontwikkeling van RTS, S in Afrika heef
  20. flosz 29 juli 2009 09:49
    quote:

    flosz schreef:

    Crucell/ MVI/ AdVac®-based malaria vaccine/ Preclinical
    Crucell/NIAID/ AdVac®-based malaria vaccine/ Clinical
    www.ifpma.org/documents/NR12400/Statu...
    Mooi, was al te lezen in de IFPMA documenten. Dacht even dat dit ook zonder pb zou blijven.

    hugin.info/132631/R/1331245/314904.pdf
439 Posts
Pagina: «« 1 ... 15 16 17 18 19 ... 22 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 918,67 +1,88%
EUR/USD 1,0867 -0,12%
FTSE 100 8.255,54 +0,29%
Germany40^ 18.595,20 +1,03%
Gold spot 2.351,67 +1,06%
NY-Nasdaq Composite 16.857,05 +0,17%

Stijgers

Xior
+5,70%
Deceun...
+3,66%
AZELIS...
+2,16%
Melexis
+1,78%
Care P...
+1,40%

Dalers

Ageas
-4,06%
Umicore
-3,17%
Tessen...
-2,96%
IBA
-2,69%
SYENSQO
-1,84%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!